23 August 2018
Visiongain’s new report Global Antibacterial Drugs Market 2017-2027: Cephalosporins, Penicillins, Fluoroquinolones, Macrolides, Carbapenems and Others indicates that the global antibacterial drugs market will see $44.54bn in spending in 2021.
The global antibacterial drugs market is expected to grow at a CAGR of 1.3% in the first half of the forecast period and a CAGR of 3.1% in the second half of the forecast period. The market is estimated at $41.76bn in 2016 and $44.54bn in 2021.
The lead analyst of the report said: ““The growth of the antibacterial drugs market has been relatively stagnant due to generic erosion, lack of new antibacterial drugs entering the market and rising prevalence of treatment-resistant bacteria. Initiatives to regulate the consumption of antibacterial drugs in several national markets, though necessary, have also hampered the growth of this market.
Current leading drugs will lose patent exclusivity from 2016 to 2027 thus opening opportunities for generics which will lead to a drop in market value. The uptake of new drugs launched within the second half of the forecast period however will stimulate that revenue growth. The overall antibacterial drug market is expected to grow with a CAGR of 2.3% from 2021-2027.”
The 304-page report contains 124 tables and 97 figures that add visual analysis to explain the developing trends within the Global Antibacterial Drugs Market. Visiongain provides revenue forecasts for the period 2017-2027.
The 304-page report offers market forecasts and analysis for the 6 leading submarkets:
• Other antibacterial drug classes
This report also forecasts the revenues of 43 leading antibacterial drugs from 2017 to 2027, including Zyvox, Cubicin, Augmentin, Zosyn/Tazocin, Avelox, Invanz and generic amoxicillin. The new survey also discusses antibacterial agents in clinical trials, examining research and development.
This report includes trends and forecast revenues in leading national markets. Countries and regions analysed are the US, the EU, Germany, France, the UK, Spain, Italy, Japan, Brazil, Russia, India, China, South Korea and the Rest of the World.
The Global Antibacterial Drugs Market 2017-2027: Cephalosporins, Penicillins, Fluoroquinolones, Macrolides, Carbapenems and Others report will be of value to anyone who wants to better understand the antibacterial drugs market and its various segments. It will be useful for businesses who wish to better comprehend the part of the market they are already involved in, or those wishing to enter or expand into a different regional or technical part of the antibacterial drugs industry.
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to email@example.com or call her on +44 (0) 207 336 6100
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, visiongain produces a host of business-to-business conferences, newsletters, management reports and e-zines focusing on the automotive, chemical, cyber, defence, energy, pharmaceutical, materials and telecoms sectors.
Visiongain publishes reports produced by its in-house analysts, who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.
Global liposomal drug delivery devices market is projected to grow at a CAGR of 10.69% by 2032.
21 June 2022
The global nanotechnology in drug delivery market was valued at US$53.0 billion in 2021 and is projected to grow at a CAGR of 18.7% during the forecast period 2022-2032.
20 June 2022
The global respiratory drug delivery technologies market was valued at US$59.51 billion in 2022 and is projected to grow at a CAGR of 7.31% during the forecast period 2022-2032.
15 June 2022
The global artificial intelligence (AI) in drug discovery market was valued at US$791 million in 2021 and is projected to grow at a CAGR of 30.7% during the forecast period 2022-2032.